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Medication blood levels 
Depression 
A B S T R A C T   
We evaluated the clinical validity of a combinatorial pharmacogenomic test and single-gene Clinical Pharma-
cogenetics Implementation Consortium (CPIC) guidelines against patient outcomes and medication blood levels 
to assess their ability to inform prescribing in major depressive disorder (MDD). 
This is a secondary analysis of the Genomics Used to Improve DEpression Decisions (GUIDED) randomized- 
controlled trial, which included patients with a diagnosis of MDD, and ≥1 prior medication failure. The abil-
ity to predict increased/decreased medication metabolism was validated against blood levels at screening 
(adjusted for age, sex, smoking status). The ability of predicted gene-drug interactions (pharmacogenomic test) 
or therapeutic recommendations (single-gene guidelines) to predict patient outcomes was validated against week 
8 outcomes (17-item Hamilton Depression Rating Scale; symptom improvement, response, remission). Analyses 
were performed for patients taking any eligible medication (outcomes N=1,022, blood levels N=1,034) and the 
subset taking medications with single-gene guidelines (outcomes N=584, blood levels N=372). The combina-
torial pharmacogenomic test was the only significant predictor of patient outcomes. Both the combinatorial 
pharmacogenomic test and single-gene guidelines were significant predictors of blood levels for all medications 
when evaluated separately; however, only the combinatorial pharmacogenomic test remained significant when 
both were included in the multivariate model. There were no substantial differences when all medications were 
evaluated or for the subset with single-gene guidelines. Overall, this evaluation of clinical validity demonstrates 
that the combinatorial pharmacogenomic test was a superior predictor of patient outcomes and medication blood 
levels when compared with guidelines based on individual genes.   
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1. Introduction 
Clinical guidelines for the treatment of major depressive disorder 
(MDD) suggest a selective serotonin reuptake inhibitor (SSRI) or sero-
tonin norepinephrine reuptake inhibitor (SNRI) as a first line treatment 
(Gelenberg et al., 2010, Kennedy et al., 2016). However, the STAR*D 
trial demonstrated that only 36% of patients achieved remission after 
first line treatment with the SSRI citalopram, and 16% of patients 
experienced intolerable side-effects (Rush et al., 2006). Medication 
failure may be linked to a number of factors that impact efficacy or 
tolerability. Alterations in medication metabolism (pharmacokinetics) 
can cause medication blood levels to be outside the therapeutic range. 
Efficacy may be inhibited if medication blood levels are too low, while 
side-effects may be associated with elevated blood levels (Fiaturi and 
Greenblatt, 2019, Florio et al., 2017, Perry et al., 1994). In addition, 
differential pharmacodynamic effects may decrease or inhibit the bio-
logical response to a medication – impacting efficacy – or trigger a 
different biological response – impacting safety or tolerability (Carr and 
Pirmohamed, 2018). 
Some factors that impact pharmacokinetics and pharmacodynamics 
may be considered as part of clinical decision-making, such as age, drug- 
drug interactions, and smoking status (Oliveira et al., 2017, Shelton, 
2019, Sultana et al., 2015). Gene-drug interactions are another impor-
tant consideration, as genetic variations in some pharmacokinetic or 
pharmacodynamic genes have been shown to impact medication effi-
cacy or safety (Jukić et al., 2018, Mrazek et al., 2011, Phillips et al., 
2018, Porcelli et al., 2012). To this end, pharmacogenomic testing has 
become more common in clinical practice in the U.S. (Dunnenberger 
et al., 2016, Cavallari et al., 2016) to support a data-driven approach to 
improve medication selection and, ultimately, patient outcomes for 
MDD. 
There are many available options for pharmacogenomic testing, and 
it is important that tests be rigorously evaluated to ensure appropriate 
clinical use and patient management (Mattocks et al., 2010, Pitini et al., 
2018, CDC, 2010). Studies can assess the ability of a pharmacogenomic 
test to improve patient outcomes when used to guide prescribing (clin-
ical utility) and the ability to identify medications unlikely to be safe or 
effective (clinical validity). Importantly, clinical validation against pa-
tient outcomes enables an evaluation of all components of a pharma-
cogenomic test, including the genes evaluated and the derived 
phenotype. A more direct method to validate the pharmacokinetic 
component of a test is to evaluate whether changes in metabolism pre-
dicted by a test correlate with changes in medication blood levels. 
Another important clinical consideration in the use of pharmacoge-
nomics to guide treatment decisions is how different approaches 
compare with each other. Clinically available tests range in design 
(single-gene, multi-gene, weighted combinatorial approach), phenotype 
assignment, and gene composition (Bousman and Dunlop, 2018, Moyer 
and Caraballo, 2017). These differences are clinically meaningful, with a 
recent meta-analysis showing that the clinical utility of three individual 
pharmacogenomic tests ranged from no clinical benefit to a 70% 
improvement in outcomes among patients with MDD (Rosenblat et al., 
2018). In addition, the Clinical Pharmacogenetics Implementation 
Consortium (CPIC) (Hicks et al., 2015, Hicks et al., 2017), Dutch Phar-
macogenetics Working Group (KNMP, 2020), and other organizations 
(FDA, 2020, Sangkuhl et al., 2011, Huddart et al., 2020) provide phar-
macogenomic guidance for many psychotropic medications commonly 
prescribed to treat depression. However, these guidelines are often 
limited to individual pharmacokinetic genes and do not account for the 
additive or off-setting effects of variation in multiple genes involved in 
medications’ metabolic pathways. 
Some pharmacogenomic tests consider the combined impact of 
variation in multiple genes on a single medication (combinatorial 
pharmacogenomics). The clinical utility and validity of one combina-
torial pharmacogenomic test has been demonstrated in several clinical 
trials among patients with MDD who have at least one prior medication 
failure (Altar et al., 2015, Hall-Flavin et al., 2013, Hall-Flavin et al., 
2012, Winner et al., 2013), including in the Genomics Used to Improve 
DEpression Decisions (GUIDED) large randomized, controlled trial 
(Greden et al., 2019). This combinatorial pharmacogenomic test 
included a weighted assessment of multiple pharmacokinetic and 
pharmacodynamic genes to provide a single, combined phenotype for 
each medication. The pharmacokinetic component of this combinatorial 
pharmacogenomic test has also been shown to predict variation in cit-
alopram and escitalopram blood levels for patients enrolled in the 
GUIDED trial (Shelton et al., 2020). 
To more broadly evaluate the clinical validity of this combinatorial 
pharmacogenomic test, we assessed its ability to predict patient out-
comes and medication blood levels for patients enrolled in the GUIDED 
trial. This included a comparison to CPIC single-gene recommendations 
based on CYP2C19 or CYP2D6. 
2. Methods 
2.1. Cohort 
All patients were enrolled in the GUIDED trial and provided written 
informed consent for participation (NCT02109939). GUIDED was a 
patient- and rater-blinded, randomized, controlled trial (approved by 
Copernicus Group independent review board INC1-14-012). The 
GUIDED trial has been previously described in detail (Greden et al., 
2019). GUIDED was conducted across 60 psychiatry and primary care 
centers in the U.S. between 2014 and 2017. Patients were eligible if they 
had a diagnosis of MDD, a score of ≥11 on the self-rated and 
clinician-rated 16-item Quick Inventory of Depressive Symptomatology 
Scale at screening and baseline. An MDD medication history log was 
completed at the screening visit. To be eligible for the GUIDED study, 
patients were also required to have had at least one failed psychotropic 
medication trial (inadequate response after 6 weeks of treatment or 
intolerable side-effects) within the current depressive episode, though 
this did not have to be the current medication trial. Patients were ran-
domized between screening and baseline to receive combinatorial 
pharmacogenomic-guided care or treatment as usual (TAU). Patients 
and raters were blinded to arm until after week 8. Providers were 
blinded to pharmacogenomic test reports for patients in TAU until after 
week 8. 
All patients were taking at least one psychotropic medication at 
screening and patients in both arms were prescribed medication during 
according to standard care (TAU) or with access to the combinatorial 
pharmacogenomic test report (intervention arm). Patients were not 
eligible for inclusion in the GUIDED trial if medication changes were 
made between screening and baseline; however, medication changes 
could be made at any point at or after the baseline visit. Because 
GUIDED was a clinical utility study designed to represent clinical 
practice, medication dose, medication duration, and concomitant med-
ications were uncontrolled and medication changes were not mandated. 
Here we present a secondary analysis of the GUIDED trial to evaluate 
the clinical validation of the combinatorial pharmacogenomic test and 
single-gene CPIC guidelines. The ability to predict variation in patient 
outcomes for both the combinatorial pharmacogenomic test and single- 
gene CPIC guidelines was validated against patient outcomes at the 
blinded week 8 endpoint. As an analysis of clinical validity to evaluate 
whether taking medications with predicted gene-drug interactions were 
correlated with worse outcomes, study arm was not pertinent. As such, 
patients were pooled from both arms to evaluate clinical validity based 
on actual medication changes. Patients were included in the outcomes 
analysis if they completed the study through week 8 and were taking at 
least one eligible medication at baseline and week 8 (Fig. 1). Eligible 
medications were those included on the combinatorial pharmacoge-
nomic test report at the time of analysis (Supplemental Table 1). 
The ability of the combinatorial pharmacogenomic test and single- 
gene CPIC guidelines to predict changes in medication metabolism 
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was validated against medication blood levels from patients enrolled in 
GUIDED. Patients were included in the blood levels analysis if they met 
study eligibility criteria at the screening visit and had blood level and 
dose information for an eligible medication (Supplemental Figure 1). 
Blood samples were collected at the screening visit. Medication blood 
levels were not returned to patients or clinicians as part of the GUIDED 
study. 
The subset of patients enrolled in GUIDED who were taking at least 
one medication in CPIC guidelines with level A (evidence is high or 
moderate in favor of changing prescribing) or level B (evidence is weak 
with little conflicting data) evidence at baseline and/or week 8 was also 
evaluated. Level A or B evidence was required for inclusion in this 
analysis based on the CPIC definition that this level of evidence supports 
“prescribing action recommended; alternative therapies or dosing are 
highly likely to be effective and safe” (CPIC, 2019). A total of 10 eligible 
medications met this criterion (amitriptyline, citalopram, desipramine, 
doxepin, escitalopram, fluvoxamine, imipramine, nortriptyline, parox-
etine, sertraline) (CPIC, 2020). Details of which medications were 
included in each analysis are in Supplemental Table 1. 
2.2. Pharmacogenomic testing 
All patients were tested with the GeneSight Psychotropic test 
(Assurex Health Inc., Mason, OH), which included an evaluation of the 
genotypes of 59 alleles and variants across 6 pharmacokinetic genes 
(CYP1A2: -3860G>A, -2467T>delT, -739T>G, -729C>T, -163C>A, 
125C>G, 558C>A, 2116G>A, 2473G>A, 2499A>T, 3497G>A, 
3533G>A, 5090C>T, 5166G>A, 5347C>T; CYP2C9: *1, *2, *3, *4, *5, 
*6; CYP2C19: *1, *2, *3, *4, *5, *6, *7, *8, *17; CYP3A4: *1, *13, *15A, 
*22; CYP2B6: *1, *4, *6, *9; CYP2D6: *1, *2, *2A, *3, *4, *5 (gene 
deletion), *6, *7, *8, *9, *10, *11, *12, *14, *15, *17, *41, gene 
duplication) and 2 pharmacodynamic genes (HTR2A: -1438 G >A; 
SLC6A4: L, S) (Jablonski et al., 2018). 
A combined phenotype was assigned based on a previously validated 
weighted assessment of individual gene phenotypes (Altar et al., 2015, 
Assurex Health, 2020). The pharmacokinetic genes were weighted based 
on the relative contribution of each enzyme to medication metabolism to 
account for any additive or off-setting effects. This was combined with 
the pharmacodynamic weights to provide a combined phenotype for 
Fig. 1. Patient flow chart for outcomes analysis. Definitions for medication congruence according to the combinatorial pharmacogenomic test or single-gene CPIC 
guidelines are also included. 
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each individual medication. The combined phenotype was used to 
categorize medications according to the level of gene-drug interactions 
(no, moderate, or significant gene-drug interactions). 
For analyses of single-gene CPIC guidelines, the individual gene 
phenotypes for CYP2C19 and CYP2D6 (ultra-rapid, rapid, extensive 
(normal), intermediate, or poor metabolizers) were assigned as 
described in CPIC guidelines (Caudle et al., 2019, Hicks et al., 2015, 
Hicks et al., 2017) using genotype data obtained in the course of 
combinatorial pharmacogenomic testing (Supplemental Table 2). No 
separate single-gene testing was performed, and no single-gene reports 
were provided. 
2.3. Patient outcomes 
The primary assessment in the GUIDED trial was the 17-item Ham-
ilton depression scale (HAM-D17) at the blinded week 8 visit. Symptom 
improvement (percent decrease in HAM-D17 from baseline to week 8), 
response (≥50% decrease in HAM-D17 from baseline to week 8), and 
remission (HAM-D17 ≤7 at week 8) were evaluated. The ability of the 
pharmacogenomic test and single-gene CPIC guidelines to predict vari-
ability in patient outcomes at week 8 according to medication congru-
ence was assessed here. 
A medication was considered congruent if prescribing that medica-
tion aligned with an individual’s pharmacogenomic information. The 
specific definition of medication congruence for the combinatorial 
pharmacogenomic test and single-gene CPIC guidelines is provided in 
Fig. 1.For the combinatorial pharmacogenomic test, medications with 
no or moderate gene-drug interactions were considered congruent and 
medications with significant gene-drug interactions were considered 
incongruent. For single-gene CPIC guidelines, medications with no 
actionable therapeutic recommendations (typically normal and inter-
mediate metabolizers for the gene of interest) were considered 
congruent and medications with actionable therapeutic recommenda-
tions (typically ultrarapid and poor metabolizers for the gene of interest) 
were considered incongruent. For the analysis of all eligible medica-
tions, those that did not have CPIC guidelines with Level A or Level B 
evidence at the time of this analysis were considered congruent with 
CPIC guidelines based on the absence of actionable guidance. 
Medication congruence was assessed at baseline and week 8. Patients 
were categorized for analysis according to medication congruence as: 1. 
change from incongruent at baseline to congruent at week 8, 2. change 
from congruent at baseline to incongruent at week 8, or 3. no change in 
medication congruence from baseline to week 8. This analysis was 
performed for all eligible medications as well as for the subset of med-
ications with CPIC guidelines. 
To assess the linear relationship between congruency category and 
outcomes, congruency category was coded numerically (details in 
Supplemental Methods). The association of the independent variable 
(the numerically coded congruency status) with each outcome was 
determined using ANCOVA for both the combinatorial pharmacoge-
nomic test and the single-gene CPIC guidelines individually. Superiority 
analyses involved including the numerically coded congruency status of 
both the combinatorial pharmacogenomic test and that of the CPIC 
guidelines as independent variables in the same model and determining 
their associations with each outcome using ANCOVA. Baseline HAM- 
D17 score was included as a covariate in all patient outcome analyses. 
All p-values were two sided and findings were considered statistically 
significant if p<0.05. All analyses were performed using R.3.6.3. 
2.4. Medication blood levels 
Medication blood concentrations were quantified as previously 
described for citalopram and escitalopram (Shelton et al., 2020). In 
brief, drug concentrations from 10μL of lysed whole blood were deter-
mined by Precera Bioscience, Inc. (Franklin, TN, USA) using liquid 
chromatography with tandem mass spectrometry and medication 
specific m/z transitions. The time since last dose and concomitant 
medications were uncontrolled. Blood levels were log base 10 trans-
formed and mean centered at zero to control for medication-specific 
differences. 
The ability of the pharmacogenomic test and CPIC guidelines to 
predict variation in medication blood levels was assessed. Medications 
were categorized according to whether the combinatorial pharmaco-
genomic test or individual gene phenotypes based on CPIC guidelines 
predicted a substantial change in medication metabolism (Supple-
mental Figure 1). For the combinatorial pharmacogenomic test, this 
included medications with significant gene-drug interactions predicted 
to increase or decrease medication metabolism. For single-gene CPIC 
guidelines, this included medications with actionable therapeutic rec-
ommendations based on an ultrarapid or poor metabolizer phenotype in 
the gene of interest. These changes were categorized as: 1. significant 
increase in medication metabolism (decrease in medication blood levels 
expected), 2. significant decrease in medication metabolism (increase in 
medication blood levels expected), or 3. no or moderate change in 
medication metabolism (no or minimal change in medication blood 
levels expected). 
To test the statistical differences between test categories and the log- 
transformed mean-centered concentration/dose ratios, ANCOVA tests 
were run using categorical variables that represent the three changes in 
metabolism described above. To test the linear relationship between the 
three test categories generated by the combinatorial pharmacogenomic 
test or by CPIC guidelines, ANCOVA tests were run with a numeric 
variable representing the directional predicted change in metabolism 
(details in Supplemental Methods). The ANCOVAs with numerically- 
transformed genetic variables were run for both tests individually to 
find the variance described by each test and another, single ANCOVA 
was run including both tests to discover the unique variance explained 
by each test. Age, smoking status, and sex were included as covariates in 
all analyses. All p-values were two sided and findings were considered 
statistically significant if p<0.05. All analyses were performed using 
R.3.6.3. 
3. Results 
3.1. Patient outcomes 
A total of 1,022 patients were taking at least one eligible medication 
at baseline and week 8 (40 total medications). This included a subset of 
584 patients who were taking at least one medication with single-gene 
guidelines at baseline or week 8 (Fig. 1). Baseline demographics and 
disease characteristics did not vary between the groups (Table 1). 
Overall patient outcomes at week 8 are summarized in Supplemental 
Table 3. We evaluated whether any clinical or demographic variables 
were associated with overall outcomes (Supplemental Table 4). Only 
smoking status (response and remission) and age (response; Supple-
mental Figure 2) were significant. 
There was a significant correlation between patient outcomes at 
week 8 and medication congruence with the combinatorial pharmaco-
genomic test, where congruent medications had no or moderate pre-
dicted gene-drug interactions. Patients who changed from incongruent 
medications at baseline to congruent medications at week 8 experienced 
the largest improvement in HAM-D17 scores when all medications were 
considered (35.2%) and within the subset of medications with single- 
gene CPIC guidelines (36.4%; Fig. 2A). Conversely, patients who 
changed from congruent medications at baseline to incongruent medi-
cations at week 8 experienced the smallest improvement in HAM-D17 
scores both for all medications (21.0%) and for the subset of medica-
tions with single-gene guidelines (17.3%; Fig. 2A). 
The same correlation trends were observed for response and remis-
sion: response and remission rates correlated with changes in medica-
tion congruence from baseline to week 8 in the analysis of all 
medications and the subset of medications with single-gene guidelines 
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(Fig. 2B and C). The highest response and remission rates were observed 
for those patients who changed from medications that were incongruent 
with the combinatorial pharmacogenomic test to congruent 
medications. 
In multivariate analysis adjusted for baseline HAM-D17 score, the 
combinatorial pharmacogenomic test was a significant predictor of 
symptom improvement when patients taking any medication included 
on the test report were evaluated (F=9.3, p=0.002; Table 2). Similarly, 
the combinatorial pharmacogenomic test was a significant predictor of 
response (χ2=4.4, p=0.036) and remission (χ2=5.0, p=0.025) for pa-
tients taking any medication included on the test report (Table 2). When 
only the subset of medications with single-gene guidelines were evalu-
ated, the combinatorial pharmacogenomic test remained a significant 
predictor of symptom improvement (F=7.7, p=0.006), response 
(χ2=4.0, p=0.046), and remission (χ2=4.1, p=0.043) at week 8 
(Table 2). 
In contrast, there was no apparent correlation between patient out-
comes at week 8 and congruence with the single-gene guidelines. For the 
analysis of all medications and the subset of medications with single- 
gene guidelines, symptom improvement at week 8 ranged from 25% 
to 35% regardless of the change in congruence with single-gene guide-
lines (Fig. 2A). Similar findings were observed for response and remis-
sion, with no correlation between response and remission rates and 
congruence with single-gene guidelines (Fig. 2B and C). 
Multivariant analysis showed that congruence with single-gene 
guidelines was not a significant predictor of symptom improvement 
(F=0.02, p=0.883), response (χ2=0.02, p=0.892), or remission 
(χ2=0.06, p=0.802) at week 8 when patients taking any eligible medi-
cation were included (Table 2). Similarly, when only the subset of 
medications with single-gene guidelines was evaluated, the single-gene 
guidelines were not a significant predictor of symptom improvement 
(F=0.1, p=0.754), response (χ2=0.13, p=0.718), or remission (χ2=0.03, 
p=0.873) at week 8 (Table 2). 
Multivariate analysis that included both the combinatorial pharma-
cogenomic test and single-gene guidelines showed that only the 
combinatorial pharmacogenomic test was significant for the evaluated 
patient outcomes. This was observed both for the analysis of all 
medications and the subset of medications with single-gene guidelines 
(Table 3). 
3.2. Blood levels 
A total of 746 patients taking at least one medication on the 
combinatorial pharmacogenomic test report at screening had blood 
level and dose information available. Some patients were taking more 
than one medication, resulting in a total of 1,034 blood levels assess-
ments for 32 medications (Supplemental Figure 1). A subset of 311 
patients were taking at least one medication with single-gene guidelines 
from CPIC (372 blood levels assessments for 10 medications). The 
baseline demographics and disease characteristics did not vary between 
the full cohort and the subset of patients taking medications with single- 
gene guidelines (Table 1). Age, sex, and smoking status were signifi-
cantly associated with the log10 concentration/dose ratios (p=6.33x10- 
5, p=2.72x10-4, p=0.04, respectively; Supplemental Figure 3). 
The log10 concentration/dose ratios were associated with the 
change in medication metabolism predicted by the combinatorial 
pharmacogenomic test and by the single-gene guidelines for all medi-
cations (Fig. 3A). Relative to patients with no/moderate predicted 
change in metabolism, there was a significant decrease in medication 
blood levels when the pharmacogenomic test predicted a significant 
increase in metabolism (B=-0.11, p=0.029). The same trend was 
observed with the single-gene guidelines, though it did not reach sta-
tistical significance (B=-0.09, p=0.068). A significant increase in 
medication blood levels was observed when a significant decrease in 
metabolism was predicted by either the combinatorial pharmacoge-
nomic test (B=0.18, p=1.12x10-6) or the single-gene guidelines 
(B=0.20, p=0.042; Fig. 3A). In this case, the relative increase in blood 
levels was similar for both; however, the combinatorial pharmacoge-
nomic test predicted a significant decrease in metabolism for 98 patients 
compared to only 13 patients for the single-gene guidelines. This reflects 
the larger number of medications for which the test provides guidance as 
well as differences in the single-gene and combinatorial approach. 
When the subset of medications with single-gene guidelines was 
assessed, both the combinatorial pharmacogenomic test and the single- 
Table 1 
Baseline characteristics.    
Patients Included in Outcomes Analysis Patients Included in Blood Levels Analysis   
All Medications* Subset with Single-Gene Guidelines All Medications* Subset with Single-Gene Guidelines 
Total 1022 584 746 311 
Age (years) Mean (SD) 48.6 (14.4) 48.3 (14.6) 49.5 (14.2) 49.1 (14.5) 
Sex, n (%) Female 720 (70.5%) 407 (69.7%) 549 (73.6%) 232 (74.6%) 
Male 302 (29.5%) 177 (30.3%) 197 (26.4%) 79 (25.4%) 
Ethnicity, n (%) Hispanic or Latino 72 (7.0%) 46 (7.9%) 41 (5.5%) 18 (5.8%) 
Not Hispanic or Latino 950 (93.0%) 538 (92.1%) 705 (94.5%) 293 (94.2%) 
Ancestry, n (%) White 839 (82.1%) 467 (80.0%) 629 (84.3%) 249 (80.1%) 
Black 140 (13.7%) 92 (15.8%) 85 (11.4%) 44 (14.1%) 
Asian 21 (2.1%) 14 (2.4%) 15 (2.0%) 10 (3.2%) 
American Indian or 
Alaskan Native 
6 (0.6%) 2 (0.3%) 4 (0.5%) 0 
Other or Multiple 16 (1.6%) 9 (1.5%) 13 (1.7%) 8 (2.6%) 
Smoker, n (%) Yes 163 (15.9%) 95 (16.3%) 113 (15.1%) 48 (15.4%) 
No 859 (84.1%) 489 (83.7%) 633 (84.9%) 263 (84.6%) 
HAM-D17 Scores Mean (SD) 21.2 (4.2) 21.2 (4.2) 21.0 (4.2) 20.9 (4.3) 
Psych Co-morbidities, n (%) General anxiety Disorder 168 (16.4%) 81 (13.9%) 136 (18.2%) 52 (16.7%) 
Panic disorders/ social 
phobia 
168 (16.4%) 81 (13.9%) 131 (17.6%) 58 (18.6%) 
Post-traumatic stress 
disorder 
53 (5.2%) 26 (4.5%) 44 (5.9%) 19 (6.1%) 
Failed Medication Trials Mean (SD) 3.6 (3.1) 3.4 (2.8) 3.8 (3.2) 3.3 (2.6) 
PGx Report Category, n (%)** No GDI 245 (24.0%) 85 (14.6%) 352 (47.2%) 199 (54.7%) 
Moderate GDI 504 (49.3%) 364 (62.3%) 248 (33.2%) 113 (31.0%) 
Significant GDI 273 (26.7%) 135 (23.1%) 146 (19.6%) 52 (14.3%) 
Abbreviations: GDI, Gene-drug interactions; HAM-D17, 17-item Hamilton depression rating scale; PGx, pharmacogenomic 
*The list of all eligible medications is provided in Supplemental Table 1 
**For patients taking more than one medication, this represents the most severe test report category 
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gene guidelines were associated with significant changes in the log10 
concentration/dose ratios corresponding with the predicted change in 
metabolism (Fig. 3B). In this subset, the combinatorial pharmacoge-
nomic test predicted that fewer patients would have a significant in-
crease in metabolism than the single-gene guidelines (16 patients versus 
56 patients); however, the decrease in blood levels was approximately 
twice as large for the combinatorial pharmacogenomic test compared to 
single-gene guidelines. Conversely, the combinatorial pharmacoge-
nomic test predicted that more patients would have a significant 
decrease in metabolism compared to the single-gene test (36 patients 
versus 13 patients) with a similar increase in medication blood levels for 
both (Fig. 3B). In this subset analysis, both the combinatorial pharma-
cogenomic test and single-gene guidelines provide guidance for all 
included medications and differences reflect the combinatorial versus 
single-gene approach. 
In multivariate analysis adjusted for age, sex and smoking status, 
both the combinatorial pharmacogenomic test (F=29.3, p=7.55x10-8) 
and single-gene guidelines (F=6.7, p=0.010) individually were signifi-
cant predictors of variance in medication blood levels when all medi-
cations were considered (Table 4). The F-statistic for the combinatorial 
pharmacogenomic test was 4-times larger than for single-gene guidance, 
showing that the pharmacogenomic test predicted more variance in 
medication blood levels than the single-gene guidelines. Similar trends 
were observed when the subset of medications with single-gene CPIC 
guidelines were assessed. Both the combinatorial pharmacogenomic test 
(F=31.4, p=4.06x10-8) and single-gene guidelines (F=9.9, p=0.002) 
were significant predictors, with the combinatorial pharmacogenomic 
test explaining a larger amount of variance in medication blood levels 
(Table 4). 
Multivariate analysis that included both the combinatorial 
Fig. 2. Patient Outcomes According to Medication Congruence. Symptom improvement, response rate, and remission rate are shown according to medication 
congruence with the combinatorial pharmacogenomic test or single-gene CPIC guidelines at baseline and week 8. Symptom improvement plots include mean 95% 
confidence intervals. Response and remission rate plots show exact 95% confidence intervals. 
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pharmacogenomic test and single-gene guidelines showed that only the 
combinatorial pharmacogenomic test remained a significant predictor of 
blood levels when all medications on the test report were included 
(F=25.0, p=6.71x10-7; Table 4). This was also observed when the 
subset of medications with single-gene guidelines was evaluated, with 
only the combinatorial pharmacogenomic test remaining significant 
(F=22.8, p=2.64x10-6; Table 4). 
4. Discussion 
As the field of pharmacogenomics has evolved, multiple methods 
have been developed to identify gene-drug interactions and then 
translate that information into clinical practice. Many professional so-
cieties and other agencies include guidance for a limited number of 
medications (FDA, 2020, CPIC, 2019, KNMP, 2020). Although this 
guidance largely focuses on individual genes, the FDA cites the need to 
evaluate “the combined effects of different genotypes” in their guidance 
on clinical drug interaction studies (U.S. Department of Health and 
Human Services Food and Drug Administration, 2020). In addition, 
some testing laboratories employ a combinatorial approach with a 
weighted assessment of multiple genes. In order to ensure appropriate 
clinical care, pharmacogenomic tests must have a robust body of evi-
dence demonstrating their clinical validity and clinical utility (Mattocks 
et al., 2010, Pitini et al., 2018, CDC, 2010). This is especially important 
with the growing number of available tests and the lack of consensus 
about what genes to include and what approach to employ (single-gene 
versus combinatorial). 
We evaluated patient outcomes at week 8 according to whether 
medications at baseline and week 8 aligned with guidance from the 
combinatorial pharmacogenomic test or with single-gene guidelines. 
This provides a direct assessment of the clinical validity for improving 
patient outcomes by following the provided guidance. In this analysis, 
only the combinatorial pharmacogenomic test was significantly corre-
lated with all evaluated patient outcomes (symptom improvement, 
response, and remission). These findings support that improved patient 
outcomes were achieved when prescribing was consistent with the gene- 
drug interactions predicted by the combinatorial pharmacogenomic test. 
The similar performance of the combinatorial pharmacogenomic test for 
all medications and the subset of medications with single-gene guide-
lines indicates that the pharmacogenomic test provides more meaning-
ful guidance for a larger group of medications than is addressed in 
current guidelines. In contrast, therapeutic recommendations in single- 
gene guidelines had no association with patient outcomes. This high-
lights a clinically relevant benefit of combinatorial pharmacogenomic 
testing to improve outcomes among this difficult to treat population of 
patients with depression who have prior medication failures. 
Variation in medication blood levels has had implied impacts on 
medication efficacy and, ultimately, patient outcomes. Because many 
professional societies focus on the impact of pharmacokinetic genes, 
there has been a significant focus on the ability to predict gene-drug 
interactions that have a clinically meaningful impact on medication 
blood levels. Combinatorial pharmacogenomic testing integrates an 
assessment of multiple pharmacokinetic genes weighted based on the 
metabolic pathway for an individual medication. As outlined by the 
PharmGKB metabolic pathways for individual medications (Huddart 
et al., 2020, Sangkuhl et al., 2011), the impact of multiple enzymes in a 
medication’s metabolic pathway provides a more complete picture of 
overall metabolism. The combinatorial pharmacogenomic test evalu-
ated here was a significant predictor of variation in medication blood 
levels for the 32 eligible medications with blood level information from 
the GUIDED study. These findings support that gene-drug interactions 
predicted by the combined, weighted assessment of multiple genes 
accurately predicted decreased blood levels due to increased meta-
bolism, and vice versa. This included the prediction of a 50% variation 
in medication blood levels when significant gene-drug interactions were 
predicted. This magnitude of variation in medication blood levels is 
largely considered clinically actionable based on implications of medi-
cation efficacy or safety. 
We also evaluated the ability of single-gene guidelines from CPIC to 
predict variation in medication blood levels. CPIC provides actionable 
guidelines for 10 antidepressants based on alterations in CYP2C19 or 
CYP2D6. For some medications, such as amitriptyline, CPIC guidelines 
do include a joint consideration of both CYP2C19 and CYP2D6 (Hicks 
et al., 2017). However, this guidance does not account for differences in 
the efficacy of secondary pathways or the relative importance of 
CYP2C19 and CYP2D6 in amitriptyline metabolism as identified by 
PharmGKB and others (PharmGKB, 2019, Breyer-Pfaff, 2004). 
Although, single-gene guidelines were a significant predictor of 
variation in medication blood levels when assessed alone, multivariate 
analysis that included both methods (single-gene guidelines and 
combinatorial pharmacogenomic testing) showed that only the combi-
natorial pharmacogenomic test remained a significant predictor of 
medication blood levels. This indicates that the combinatorial pharma-
cogenomic test accounts for all medication blood level variance 
addressed by single-gene guidelines and adds significant, independent 
information. This finding was true when all eligible medications were 
considered as well as when the subset of medications with single-gene 
guidelines were considered. In addition, the similar performance in 
the analysis of all medications and the subset with guidelines highlights 
the fact that the addition of medications without single-gene guidelines 
did not dilute the performance of the combinatorial pharmacogenomic 
test. Collectively, these findings support that although existing CPIC 
Table 2 
Separate Evaluation of the Combinatorial Pharmacogenomic Test and Single- 
Gene Guidelines to Predict Patient Outcomes. The individual models shown 
here included either the combinatorial pharmacogenomic test or single-gene 




Outcome F-Statistic or χ2 P- 
Value 
F-Statistic or χ2 P- 
Value 




9.3 0.002 0.02 0.883 
Response 4.4 0.036 0.02 0.892 
Remission 5.0 0.025 0.06 0.802 
Patients Taking Medications with Single-Gene Guidelines (N=584) 
Symptom 
Improvement 
7.7 0.006 0.1 0.754 
Response 4.0 0.046 0.13 0.718 
Remission 4.1 0.043 0.03 0.873  
Table 3 
Combined Evaluation of the Combinatorial Pharmacogenomic Test and Single- 
Gene Guidelines to Predict Patient Outcomes. The combined models shown 
here included both the combinatorial pharmacogenomic test and single-gene 




Outcome F-Statistic or χ2 P- 
Value 
F-Statistic or χ2 P- 
Value 




9.4 0.002 0.15 0.695 
Response 4.5 0.034 0.099 0.754 
Remission 5.0 0.026 0.004 0.947 
Patients Taking Medications with Single-Gene CPIC Guidelines (N=584) 
Symptom 
Improvement 
7.9 0.005 0.38 0.539 
Response 4.2 0.041 0.35 0.556 
Remission 4.1 0.044 0.004 0.947  
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guidelines related to CYP2C19 and CYP2D6 provide some information 
about changes in metabolism, combinatorial pharmacogenomic testing 
(e.g. a weighted assessment of multiple genes associated with the 
pharmacokinetics for a specific medication) was a superior assessment. 
There were some limitations of this analysis. GUIDED was not a 
controlled pharmacokinetics study. As such, blood levels were not 
controlled for time of intake or medication adherence. Further, patient 
inclusion was not limited by concomitant medications (e.g., medications 
known to impact drug metabolism). In addition, blood levels were only 
collected at screening and could not be directly correlated with 
outcomes or adverse events. 
In summary, this evaluation of clinical validity shows that only the 
combinatorial pharmacogenomic test was significantly associated with 
improved patient outcomes. In addition, the combinatorial pharmaco-
genomic test was a superior predictor of medication blood levels across a 
larger group of medications relative to guidelines focused on only 
CYP2C19 and CYP2D6. These data suggest that the superior ability of 
combinatorial pharmacogenetic testing to predict variation in medica-
tion blood levels may result in improved patient outcomes. Given the 
variety of approaches employed in pharmacogenomic testing between 
professional societies, government associations, and testing labora-
tories, it is critical that tests have robust evidence of validity and utility. 
Collectively, the data presented here provide compelling evidence of the 
clinical validity of the combinatorial pharmacogenomic test in a large 
cohort of patients with MDD who have at least one prior medication 
failure. 
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